WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
She was happily married, pregnant with her first child and had recently completed her residency in family medicine. Soon ...
Richard Balanson says when one suffers a disease "you begin to accumulate friends" who have their own story with the same ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback